‘Executive Order: Declaring A Disaster In The State Of New York’
https://www.governor.ny.gov/executive-order/no-21-declaring-disaster-state-new-york
E X E C U T I V E O R D E R
DECLARING A DISASTER IN THE
‘U.S. Clinical Trial Evaluating Antiviral For Monkeypox Begins, NIH Trial Gathering Data On Tecovirimat (TPOXX)’ – National Institute Of Allergy And Infectious Diseases
https://www.niaid.nih.gov/news-events/us-clinical-trial-evaluating-antiviral-monkeypox-begins
There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…
‘Highly Compelling’ Eye Drug Data Has Wall Street Stampeding To Buy This ‘Large Cap Growth Story.’ Even After $15B In Market Cap Was Added
Morgan Stanley upgraded Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) to Overweight from Equal Weight with a price target of $851, up from $625. The analyst…
BioNTech Presents Phase 1/2 Follow-Up Data For CAR-T Candidate BNT211 In Hard-To-Treat Solid Tumors At European Society for Medical Oncology
Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in April
Strongest
U.S. FDA And European Medicines Agency Accepted Pfizer’s Hair Loss Candidate Submission For Review
The U.S. Food and Drug Administration (FDA) has accepted for review Pfizer’s (NYSE: PFE) New Drug Application (NDA) for ritlecitinib for adults and adolescents 12 years of age and older with alopecia areata.
The regulatory agency is expected to make a decision in the second-quarter of 2023.
After Disappointing Data, Allakos Discontinues Work On Lirentelimab In Eosinophilic Gastrointestinal Diseases
Allakos Inc (NASDAQ: ALLK) has reported data from the EoDyssey Phase 3 study of lirentelimab in patients with eosinophilic duodenitis (EoD).
Novartis’ Kisqali Adds One More Year Of Survival Benefit In Breast Cancer Setting
Novartis AG (NYSE:NVS) has announced results from a new pooled exploratory analysis of the MONALEESA Phase 3 program of Kisqali +…
Arcutis Biotherapeutics Presents Data From STRATUM Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Seborrheic Dermatitis Presented At European Academy Of Dermatology And Venereology Congress
Study met its primary endpoint with 80% of individuals treated with roflumilast foam achieving Investigator Global Assessment (IGA) Success compared to 59% of patients treated with vehicle